Skip to main content
  • Home
  •  The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM

The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM

Topic:
  • Amyloidosis

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

No ratings

Overview

Radcliffe Medical Education bring together a globally-renowed faculty, first presented at ESC 2024, including Prof Julian Gillmore (University College London, London, UK) lead a distinguished faculty compromising of Dr Ahmad Masri (Oregon Health & Science University Medical Group, Portland, US), Dr Margot Davis (University of British Columbia, Vancouver, CA), and Dr Giuseppe Vergaro (Sant’Anna, Pisa, IT).
 

The faculty present recent epidemiological data on ATTR-CN incidence and trends. The session will teach how to identify patients who undergo detailed diagnosis and list the red flags indicating ATTR amyloidosis. 

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

The session, ‘The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionalsand the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Support Statement

This activity is supported by an unrestricted educational grant from AstraZeneca. AstraZeneca has had no involvement in the selection of the speakers, the development of the activity, the agenda or the materials.

Instruction to Participants

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within 90 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

  • Heart Failure Specialists
  • Cardiac Amyloidosis Specialists
  • Echocardiologists

Learning Objectives

  • Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends
  • List red flags indicating the presence of ATTR amyloidosis
  • Identify patients who should undergo detailed diagnosis work-up or referral
  • List the advantages of emerging classes of agents being evaluated in ATTR-CM
Register now Log in

Module

Title

Duration

Speakers

Chapter 1 Welcome and Introduction 2m 49s Julian Gillmore
Chapter 2 A Contemporary View of ATTR-CM Epidemiology 11m 55s Margot Davis
Chapter 3 Practical Screening: What's the Role of the Cardiologist? 14m 35s Giuseppe Vergaro
Chapter 4 Where Are We Now and What’s Next in Medical Management? 17m 6s Ahmad Masri
Sesion 5 Closing Remarks 12m 10s Julian Gillmore Ahmad Masri Margot Davis Giuseppe Vergaro
Chapter 1.

Welcome and Introduction

Duration: 2m 49s

Speakers: Julian Gillmore

Chapter 2.

A Contemporary View of ATTR-CM Epidemiology

Duration: 11m 55s

Speakers: Margot Davis

Chapter 3.

Practical Screening: What's the Role of the Cardiologist?

Duration: 14m 35s

Speakers: Giuseppe Vergaro

Chapter 4.

Where Are We Now and What’s Next in Medical Management?

Duration: 17m 6s

Speakers: Ahmad Masri

Sesion 5.

Chair

Julian Gillmore

University College London, London, UK

Julian Gillmore gained his medical degree at University of London. He trained in nephrology and undertook MD and PhD degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis.

View full profile

Speaker

Ahmad Masri

Oregon Health & Science University Medical Group, Portland, USA

Dr Ahmad Masri M.D., M.S. trained in Internal Medicine at the Cleveland Clinic.

He specialises in caring for patients with conditions that result in abnormally thickened hearts, such as hypertrophic cardiomyopathy, amyloidosis and Fabry’s disease.

View full profile

Speaker

Margot Davis

University of British Columbia (UBC) Cardiology-Oncology Program, Vancouver General Hospital, Vancouver, Canada

FRCPC MD

Dr Margot Davis is a cardiologist at Vancouver General Hospital and St. Paul's Hospital, as well as the director of the UBC Cardiology-Oncology Program and a clinical assistant professor at the University of British Columbia (UBC).

View full profile
1.00 EBAC

The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.

Related Courses

Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
  • 1.00 EBAC

Learning objectives

  • Understand the nature of amyloidosis and its effects on various organs, particularly the heart
  • Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
  • Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
  • Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
  • Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
  • Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
See more
Challenges in ATTR Amyloidosis: An Expert Debate
  • 1.00 EBAC

Learning objectives

  • Comprehend the unique challenges posed to cardiologists who encounter patients with ATTR amyloidosis
  • Initiate first steps in diagnosis of suspect individuals in accordance to latest guidance
  • Have enhanced awareness of the disease trajectory of patients with a mixed ATTR phenotype
  • Recall the limitations of existing therapies for ATTR-CM
  • List the advantages of emerging classes of agents being evaluated in ATTR-CM
See more